Skip to main content

New Laboratory Insights for the ANA+ Consult A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can p

Social Author Name
Dr. John Cush
Tweet Content
New Laboratory Insights for the ANA+ Consult A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD). https://t.co/vw4CMf6F0R https://t.co/moJcOr1LYf

Differential Dx of Granulomatous Myopathy: Sarcoidosis, inclusion-body myositis, myasthenia gravis, Crohns, GPA, TB, bru

Social Author Name
Dr. John Cush
Tweet Content
Differential Dx of Granulomatous Myopathy: Sarcoidosis, inclusion-body myositis, myasthenia gravis, Crohns, GPA, TB, brucellosis, syphilis, PBC, RA, systemic sclerosis , lymphoma, checkpoint inhibitors, GVHD, natural killer/T-cell lymphoma https://t.co/5IUaC1ln7G https://t.co/guYtvyaaHU

S.Korean population based study shows the frequency of pregnancy induced de Quervain's tenosynovitis (DQT) between 2013-

Social Author Name
Dr. John Cush
Tweet Content
S.Korean population based study shows the frequency of pregnancy induced de Quervain's tenosynovitis (DQT) between 2013-17 was 2.1% of all preg women. Risk factors: ≥ 30 yrs, multiple gestation, C-Section, HTN in preg, RA (DM not a risk) https://t.co/JaOQhaX5rL https://t.co/cl6RZLfXds

Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppres

Social Author Name
Dr. John Cush
Tweet Content
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppressants & CTX. Case 1 SLEDAI from 13 to 2 in 24 weeks & CLASI-A from 26 to 3 in 20wks. Cs 2 CLASI-A decr 24 to 5 after 1 infusion https://t.co/Qe2rF4Avxe

Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/ b/tsDMARDs. Pooled HBV reactivation =

Social Author Name
Dr. John Cush
Tweet Content
Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/ b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−) RTX 9% (p .03) ABA 6% JAKi 1% IL‐6i 0% TNFi 0% Safe to use TNFi, JAKi, IL6 mAbs https://t.co/U76or69bnB https://t.co/5QbR3WqzUG
Subscribe to
×